A detailed history of Burleson & Company, LLC transactions in Genprex, Inc. stock. As of the latest transaction made, Burleson & Company, LLC holds 400 shares of GNPX stock, worth $640. This represents 0.0% of its overall portfolio holdings.

Number of Shares
400
Previous 400 -0.0%
Holding current value
$640
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 12, 2021

BUY
$3.66 - $7.67 $1,464 - $3,068
400 New
400 $2,000

Others Institutions Holding GNPX

# of Institutions
2
Shares Held
600
Call Options Held
0
Put Options Held
0

About Genprex, Inc.


  • Ticker GNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,300
  • Market Cap $76.8M
  • Description
  • Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...
More about GNPX
Track This Portfolio

Track Burleson & Company, LLC Portfolio

Follow Burleson & Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Burleson & Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Burleson & Company, LLC with notifications on news.